1335041-46-7

Basic information

• Product Name: 3-(4-Aminophenyl)-N-methylbenzamide
• Synonyms: 3-(4-Aminophenyl)-N-methylbenzamide;4'-AMino-N-Methyl-[1,1'-biphenyl]-3-carboxaMide
• CAS NO: 1335041-46-7
• Molecular Formula: C14H14N2O
• Molecular Weight: 226.27376
• Mol File: 1335041-46-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(4-Aminophenyl)-N-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Aminophenyl)-N-methylbenzamide(1335041-46-7)
• EPA Substance Registry System: 3-(4-Aminophenyl)-N-methylbenzamide(1335041-46-7)

Safety Data

• Hazardous Substances Data: 1335041-46-7(Hazardous Substances Data)

Usage

Chemical classification

Benzamide derivative

Substitutions

Methyl group at the nitrogen atom, aminophenyl group at the 3-position of the benzene ring

Potential applications

Pharmaceutical and chemical industries

Uses

Potential drug candidate, building block for synthesis of other chemical compounds

Future research

Further testing and research required to determine specific properties and applications

Upstream product

• 729-01-1 4'-nitrobiphenyl-3-carboxylic acid 
• 25487-66-5 3-Carboxyphenylboronic acid 
• 586-78-7 para-nitrophenyl bromide 
• 1598408-84-4 C₁₄H₁₂N₂O₃ 

Downstream Products

• 620963-03-3 1-(4-(3-(Methylcarbamoyl)phenyl)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea 

Relevant articles and documents

Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents

A novel series of diaryl ureas containing different linker groups were designed and synthesized. Their in vitro antitumor activity against MX-1, A375, HepG2, Ketr3 and HT-29 was evaluated using the standard MTT assay. Compounds having a rigid linker group such as vinyl, ethynyl and phenyl showed significant inhibitory activity against a variety of cancer cell lines. Specifically, compound 23 with a phenyl linker group demonstrated broad-spectrum antitumor activity with IC50 values of 5.17-6.46 μM against five tested tumor cell lines. Compound 23 is more potent than reference drug sorafenib (8.27-15.2 μM), representing a promising lead for further optimization.